Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1978 2
1979 1
1996 1
1999 2
2000 2
2002 2
2005 1
2006 2
2007 4
2008 4
2009 4
2010 4
2011 5
2012 9
2013 13
2014 29
2015 31
2016 21
2017 18
2018 15
2019 9
2020 20
2021 30
2022 29
2023 39
2024 40
2025 24

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

314 results

Results by year

Filters applied: . Clear all
Page 1
Regulated induced proximity targeting chimeras-RIPTACs-A heterobifunctional small molecule strategy for cancer selective therapies.
Raina K, Forbes CD, Stronk R, Rappi JP Jr, Eastman KJ, Zaware N, Yu X, Li H, Bhardwaj A, Gerritz SW, Forgione M, Hundt A, King MP, Posner ZM, Correia AD, McGovern A, Puleo DE, Chenard R, Mousseau JJ, Vergara JI, Garvin E, Macaluso J, Martin M, Bassoli K, Jones K, Garcia M, Howard K, Yaggi M, Smith LM, Chen JM, Mayfield AB, De Leon CA, Hines J, Kayser-Bricker KJ, Crews CM. Raina K, et al. Among authors: mcgovern a. Cell Chem Biol. 2024 Aug 15;31(8):1490-1502.e42. doi: 10.1016/j.chembiol.2024.07.005. Epub 2024 Aug 7. Cell Chem Biol. 2024. PMID: 39116881 Free PMC article.
Regulated Induced Proximity Targeting Chimeras (RIPTACs): a Novel Heterobifunctional Small Molecule Therapeutic Strategy for Killing Cancer Cells Selectively.
Raina K, Forbes CD, Stronk R, Rappi JP Jr, Eastman KJ, Gerritz SW, Yu X, Li H, Bhardwaj A, Forgione M, Hundt A, King MP, Posner ZM, Denny A, McGovern A, Puleo DE, Garvin E, Chenard R, Zaware N, Mousseau JJ, Macaluso J, Martin M, Bassoli K, Jones K, Garcia M, Howard K, Smith LM, Chen JM, De Leon CA, Hines J, Kayser-Bricker KJ, Crews CM. Raina K, et al. Among authors: mcgovern a. bioRxiv [Preprint]. 2023 Jan 2:2023.01.01.522436. doi: 10.1101/2023.01.01.522436. bioRxiv. 2023. Update in: Cell Chem Biol. 2024 Aug 15;31(8):1490-1502.e42. doi: 10.1016/j.chembiol.2024.07.005. PMID: 36711980 Free PMC article. Updated. Preprint.
Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.
Coutts SB, Ankolekar S, Appireddy R, Arenillas JF, Assis Z, Bailey P, Barber PA, Bazan R, Buck BH, Butcher KS, Camden MC, Campbell BCV, Casaubon LK, Catanese L, Chatterjee K, Choi PMC, Clarke B, Dowlatshahi D, Ferrari J, Field TS, Ganesh A, Ghia D, Goyal M, Greisenegger S, Halse O, Horn M, Hunter G, Imoukhuede O, Kelly PJ, Kennedy J, Kenney C, Kleinig TJ, Krishnan K, Lima F, Mandzia JL, Marko M, Martins SO, Medvedev G, Menon BK, Mishra SM, Molina C, Moussaddy A, Muir KW, Parsons MW, Penn AMW, Pille A, Pontes-Neto OM, Roffe C, Serena J, Simister R, Singh N, Spratt N, Strbian D, Tham CH, Wiggam MI, Williams DJ, Willmot MR, Wu T, Yu AYX, Zachariah G, Zafar A, Zerna C, Hill MD; TEMPO-2 investigators. Coutts SB, et al. Lancet. 2024 Jun 15;403(10444):2597-2605. doi: 10.1016/S0140-6736(24)00921-8. Epub 2024 May 17. Lancet. 2024. PMID: 38768626 Clinical Trial.
Endovascular Treatment of Stroke Due to Medium-Vessel Occlusion.
Goyal M, Ospel JM, Ganesh A, Dowlatshahi D, Volders D, Möhlenbruch MA, Jumaa MA, Nimjee SM, Booth TC, Buck BH, Kennedy J, Shankar JJ, Dorn F, Zhang L, Hametner C, Nardai S, Zafar A, Diprose W, Vatanpour S, Stebner A, Bosshart S, Singh N, Sebastian I, Uchida K, Ryckborst KJ, Fahed R, Hu SX, Vollherbst DF, Zaidi SF, Lee VH, Lynch J, Rempel JL, Teal R, Trivedi A, Bode FJ, Ogungbemi A, Pham M, Orosz P, Abdalkader M, Taschner C, Tarpley J, Poli S, Singh RJ, De Leacy R, Lopez G, Sahlas D, Chen M, Burns P, Schaafsma JD, Marigold R, Reich A, Amole A, Field TS, Swartz RH, Settecase F, Lenzsér G, Ortega-Gutierrez S, Asdaghi N, Lobotesis K, Siddiqui AH, Berrouschot J, Mokin M, Ebersole K, Schneider H, Yoo AJ, Mandzia J, Klostranec J, Jadun C, Patankar T, Sauvageau E, Lenthall R, Peeling L, Huynh T, Budzik R, Lee SK, Makalanda L, Levitt MR, Perry RJ, Hlaing T, Jahromi BS, Singh P, Demchuk AM, Hill MD; ESCAPE-MeVO Investigators. Goyal M, et al. N Engl J Med. 2025 Apr 10;392(14):1385-1395. doi: 10.1056/NEJMoa2411668. Epub 2025 Feb 5. N Engl J Med. 2025. PMID: 39908448 Clinical Trial.
A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study.
Dennis JM, Young KG, Cardoso P, Güdemann LM, McGovern AP, Farmer A, Holman RR, Sattar N, McKinley TJ, Pearson ER, Jones AG, Shields BM, Hattersley AT; MASTERMIND Consortium. Dennis JM, et al. Among authors: mcgovern ap. Lancet. 2025 Mar 1;405(10480):701-714. doi: 10.1016/S0140-6736(24)02617-5. Epub 2025 Feb 25. Lancet. 2025. PMID: 40020703 Free article.
Precision subclassification of type 2 diabetes: a systematic review.
Misra S, Wagner R, Ozkan B, Schön M, Sevilla-Gonzalez M, Prystupa K, Wang CC, Kreienkamp RJ, Cromer SJ, Rooney MR, Duan D, Thuesen ACB, Wallace AS, Leong A, Deutsch AJ, Andersen MK, Billings LK, Eckel RH, Sheu WH, Hansen T, Stefan N, Goodarzi MO, Ray D, Selvin E, Florez JC; ADA/EASD PMDI; Meigs JB, Udler MS. Misra S, et al. Commun Med (Lond). 2023 Oct 5;3(1):138. doi: 10.1038/s43856-023-00360-3. Commun Med (Lond). 2023. PMID: 37798471 Free PMC article.
Precision treatment of beta-cell monogenic diabetes: a systematic review.
Naylor RN, Patel KA, Kettunen JLT, Männistö JME, Støy J, Beltrand J, Polak M; ADA/EASD PMDI; Vilsbøll T, Greeley SAW, Hattersley AT, Tuomi T. Naylor RN, et al. Commun Med (Lond). 2024 Jul 18;4(1):145. doi: 10.1038/s43856-024-00556-1. Commun Med (Lond). 2024. PMID: 39025920 Free PMC article.
A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patients.
Lim-Fat MJ, Cotter JA, Touat M, Vogelzang J, Sousa C, Pisano W, Geduldig J, Bhave V, Driver J, Kao PC, McGovern A, Ma C, Margol AS, Cole K, Smith A, Goldman S, Kaneva K, Truong A, Nazemi KJ, Wood MD, Wright KD, London WB, Warren KE, Wen PY, Bi WL, Alexandrescu S, Reardon DA, Ligon KL, Yeo KK. Lim-Fat MJ, et al. Among authors: mcgovern a. Neuro Oncol. 2024 Dec 5;26(12):2364-2376. doi: 10.1093/neuonc/noae142. Neuro Oncol. 2024. PMID: 39082676 Free PMC article.
314 results